Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
Rattachement africain : in, be, de, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Traditional Histone deacetylase 8 (HDAC8) inhibitors primarily rely on hydroxamate-based scaffolds. However, there is a growing interest in developing non-hydroxamate inhibitors to overcome potential limitations with hydroxamate-based inhibitors. In this study, we report the design, synthesis, and evaluation of a series of benzyl-1,2,4-triazolo[4,3-a] pyridine derivatives as non-hydroxamate HDAC8 inhibitors. Their HDAC8 inhibitory activities were assessed by enzymatic assay. Active compounds from the HDAC8 enzymatic assay were evaluated in various cancer cell lines, revealing that compound 9i demonstrated significant anti-neuroblastoma activity. Docking studies on compound 9i were conducted to explicate its structural basis. The additional experiments showed that compound 9i inhibited colony formation, induced hyperacetylation of SMC3, suppressed cell migration, triggered apoptosis, and caused cell cycle arrest in IMR-32 neuroblastoma cells. Overall, these inhibitors showed promising activity and a strong correlation with observed phenotypic effects, suggesting their potential for further development as therapeutic agents for cancer treatment. • A series of 22 benzyl-1,2,4-triazolo[4,3-a] pyridine derivatives was synthesized and biologically characterized. • The development of these non-hydroxamate HDAC8 inhibitors avoids the problematic hydroxamate warhead. • Compound 9i showed significant activity in colony formation, cell migration, apoptosis and cell cycle arrest assays using neuroblastoma cells. • The basic pharmacophor has promising potential for further optimization towards drug candidates against neuroblastoma and other HDAC8-related diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
- Date Crossref
- 01/04/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Birla Institute of Technology and Science - Hyderabad Campus Department of Chemistry pays non établi dans la noticeUniversité ou école supérieure
-
Aurigene Discovery Technologies (India) pays non établi dans la noticeEntreprise
-
Birla Institute of Technology and Science pays non établi dans la noticeUniversité ou école supérieure
-
European Union pays non établi dans la noticeOrganisme public
-
Technische Universität Darmstadt pays non établi dans la noticeUniversité ou école supérieure
-
EU Business School pays non établi dans la noticeUniversité ou école supérieure
-
Aurigene Oncology Limited pays non établi dans la noticeInstitution
-
University of Applied Sciences Darmstadt Department of Chemical Engineering and Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
European University of Technology pays non établi dans la noticeUniversité ou école supérieure
Department of Chemistry — Birla Institute of Technology and Science - Hyderabad Campus, Aurigene Discovery Technologies (India) et Birla Institute of Technology and Science, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.